6.9% reported weight loss · 0.8% gain with placebo · 13 weeks
60 mg once daily
US adults with obesity, or overweight with a weight-related comorbidity; type 1 and type 2 diabetes excluded
Sponsor table reports mean (SE) percent change; formal estimand and intercurrent-event strategy are not specified. Global AURORA phase 3 weight-management program first participant dosed August 30, 2026; results expected in 2028.
Safety context
60 mg arm: vomiting 30%, nausea 40%, diarrhea 20%; no adverse-event discontinuations in that arm.
Limitations: Only 20 participants in the highest-dose arm; sponsor analysis without a defined estimand. The 7.7% headline is placebo-adjusted, whereas absolute mean loss is 6.9% because placebo gained 0.8%.
No approved trade name verified as of September 13, 2026; the compound name and development codes are not trade names.
Ascletis Pharma · Originator and global developer of oral and depot-injection formulations.
Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
The molecule
A small molecule that activates GLP-1 receptors; the sponsor describes its receptor signaling as fully biased.
Structure not yet verified
Structure not verified
A small molecule that activates GLP-1 receptors; the sponsor describes its receptor signaling as fully biased.
Shown: Small-molecule drug
An exact-drug structure was not verified in this review. The named PubChem lookup did not return a compound record; no related hormone or analogue is substituted.